Doxecitine and doxribtimine are combination medications used to treat a rare genetic condition called Thymidine Kinase 2 (TK2) deficiency. These medications are pyrimidine nucleosides that help replace missing components in cells affected by TK2 deficiency. They work together to support proper cellular function in patients with this condition.

dCMP/dTMP is a combination treatment that works similarly to doxecitine and doxribtimine. It is another form of pyrimidine nucleoside therapy used to treat TK2 deficiency by helping to restore normal cellular processes in patients with this genetic condition.

dC/dT (combination pyrimidine nucleosides) is another formulation of treatment that contains similar active components to help patients with TK2 deficiency. Like the other medications in this trial, it works by providing the body with important cellular building blocks that are lacking due to the genetic condition.

Thymidine Kinase 2 Deficiency – A rare genetic condition that affects the body’s ability to produce mitochondrial DNA. The disease causes progressive muscle weakness due to problems with an enzyme called thymidine kinase 2, which is essential for producing DNA building blocks in mitochondria. It primarily affects muscle tissues throughout the body, including those used for movement, breathing, and swallowing. The condition can begin in childhood or adulthood, with varying rates of progression. People with this condition may experience difficulty with physical activities and movements that were previously normal for them.